Table of Contents 2
List of Tables 8
List of Figures 8
Shire Plc Spshot 9
Shire Plc Overview 9
Key Information 9
Key Facts 9
Shire Plc - Research and Development Overview 10
Key Therapeutic Areas 10
Shire Plc - Pipeline Review 14
Pipeline Products by Stage of Development 14
Pipeline Products - Monotherapy 15
Pipeline Products - Partnered Products 16
Partnered Products/Combition Treatment Modalities 17
Pipeline Products - Out-Licensed Products 18
Out-Licensed Products/Combition Treatment Modalities 19
Shire Plc - Pipeline Products Glance 20
Shire Plc - Late Stage Pipeline Products 20
Pre-Registration Products/Combition Treatment Modalities 20
Phase III Products/Combition Treatment Modalities 21
Shire Plc - Clinical Stage Pipeline Products 22
Phase II Products/Combition Treatment Modalities 22
Phase I Products/Combition Treatment Modalities 23
Shire Plc - Early Stage Pipeline Products 24
Preclinical Products/Combition Treatment Modalities 24
Shire Plc - Unknown Stage Pipeline Products 25
Unknown Products/Combition Treatment Modalities 25
Shire Plc - Drug Profiles 26
guanfacine hydrochloride ER 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
lifitegrast 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
parathyroid hormone 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
agalsidase alfa 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
budesonide 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
C1 esterase inhibitor (human) 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
icatibant acetate 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ladelumab 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
lisdexamfetamine dimesylate 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
prucalopride succite 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
SHP-465 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
teduglutide (recombint) 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
idursulfase 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
maribavir 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
mecasermin rinfabate (recombint) 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
revexepride 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
SHP-610 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
SHP-625 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
SHP-635 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
SHP-640 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
VP-20621 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
SHP-611 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
SHP-622 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
SHP-623 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
SHP-627 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
volixibat potassium 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Drugs for Rare Diseases 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
DX-2507 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
DX-4012 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Gene Therapy to Activate GTP Cyclohydrolase I for Parkinson’s Disease 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
HTL-1071 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Monoclol Antibodies for Genetic Diseases 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
SC-435 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
SHP-630 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
SHP-637 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
SHP-639 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
SHP-641 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
etiguanfacine 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Shire Plc - Pipeline Alysis 83
Shire Plc - Pipeline Products by Target 83
Shire Plc - Pipeline Products by Route of Administration 85
Shire Plc - Pipeline Products by Molecule Type 86
Shire Plc - Pipeline Products by Mechanism of Action 87
Shire Plc - Recent Pipeline Updates 89
Shire Plc - Dormant Projects 126
Shire Plc - Discontinued Pipeline Products 128
Discontinued Pipeline Product Profiles 128
NRP-290 128
SPD-452 129
SPD-453 129
SPD-756 129
ALX-0646 129
BMN-185 129
C1 esterase inhibitor (human) 129
CX-516 129
ecallantide 130
HCV-796 130
HGT-1111 130
HGT-2610 130
icatibant acetate 130
isovaleramide 130
lisdexamfetamine dimesylate 130
mesalamine ER 131
metoclopramide hydrochloride 131
ramatercept 131
SHP-557 131
SHP-613 131
SHP-628 131
SPD-491 131
SPD-554 131
SPD-556 132
valrocemide 132
Shire Plc - Company Statement 133
Shire Plc - Locations And Subsidiaries 136
Head Office 136
Other Locations & Subsidiaries 136
Shire Plc - Key Manufacturing Facilities 143
Appendix 144
Methodology 144
Coverage 144
Secondary Research 144
Primary Research 144
Expert Panel Validation 144
Contact Us 144
Disclaimer 145